Results 151 to 160 of about 5,437,492 (305)

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

[Orange Daily Leader Building}

Photograph of the Orange Daily Leader building. An automobile is parked nearby.

core  

Superior outcomes with offspring B-leader-matched haploidentical versus older matched sibling donors in AL/MDS patients aged ≥40 years. [PDF]

Front Immunol
Wei Y, Tang J, Yang R, Shao Y, Luan S, Wang L, Wang L, Li F, Wu Y, Qian K, Peng B, Zhang H, Ge D, Fang Y, Huang L, Liu Q, Dou L, Liu D.   +17 more
europepmc   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Finlands Leader+ -program

, 2001
Under programperioden 2000–2006 kommer strukturfondsprogrammen mål 1, 2 och 3 samt gemenskapsinitiativen LEADER+, INTERREG III, EQUAL och URBAN att genomföras i Finland. Vidare kommer det att genomföras horisontella och regionala program för utvecklingen

core  

How Medicaid Accountable Care Organizations Advance Maternal Health Care Quality: Drivers of Change and Challenges From the Perspective of ACO Leaders, Clinicians, and Care Coordinators. [PDF]

Milbank Q
Ogden SN, Loo S, Cole MB, Thompson KD, Lim KN, Gordon SH, Ncube CN, Patton EW, Lasser KE, McCloskey L.   +9 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Orange Leader Journalists

Photograph of two journalists of the Orange Leader newspaper. The man on the left is J. Cullen Browning, editor and later vice president of the Orange Leader.

core  

The role of LEADER programme in the development of Vámospércs

, 2010
A dolgozatban bemutatom az Európai Unió egyik legnépszerűbb vidékfejlesztési programját, a LEADER programot, valamint annak szerepét Vámospércs városának fejlődésében.
Szabó, Gergő
core  

Co-Creation and Usability Testing of a Digital Cardiac Rehabilitation Program (eCardiacRehab): Design and Development Study. [PDF]

JMIR Cardio
Nordfonn OK, Johnsen Ramstad K, Roed Pettersen T, Hjertvikrem N, Aamot Aksetøy IL, Agcaoili Borge AJ, Gerdts E, Hesthammer JG, Hole T, Instenes I, Isaksen A, Krumsvik OA, Landaas M, Moltu C, Rotevatn S, Schjøtt J, Sommersten CH, Tryti JO, Norekvål TM.   +18 more
europepmc   +1 more source